Tag Archives: Yi Chen

Alimera (ALIM) Receives a Rating Update from a Top Analyst

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Alimera (ALIM – Research Report), with a price target of $16.00. The company’s shares closed last Wednesday at $10.97, close to its 52-week high of

AzurRx BioPharma (AZRX) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on AzurRx BioPharma (AZRX – Research Report) today and set a price target of $2.50. The company’s shares closed last Tuesday at $0.79, close to its 52-week low of $0.56. According

H.C. Wainwright Thinks Bio-Path Holdings’ Stock is Going to Recover

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bio-Path Holdings (BPTH – Research Report), with a price target of $12.00. The company’s shares closed last Monday at $6.27, close to its 52-week low

Motus Gi Holdings (MOTS) Received its Third Buy in a Row

After Colliers Securities and Oppenheimer gave Motus Gi Holdings (NASDAQ: MOTS) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Yi Chen reiterated a Buy rating on Motus Gi Holdings today and set

AzurRx BioPharma (AZRX) Received its Third Buy in a Row

After Roth Capital and Maxim Group gave AzurRx BioPharma (NASDAQ: AZRX) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Yi Chen reiterated a Buy rating on AzurRx BioPharma today and set a

H.C. Wainwright Reaffirms Their Buy Rating on Check-Cap (CHEK)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Check-Cap (CHEK – Research Report), with a price target of $4.00. The company’s shares closed last Monday at $3.07. According to TipRanks.com, Chen is a